Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AZD5004 in Healthy Volunteers (MAD and Bioavailability)
NCT06555822Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of elecoglipron in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events (AEs) and serious adverse events (SAEs), Maximum observed plasma drug concentration and 3 more. Started Aug 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06555822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555822.